Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of the general formula (I)



(I)

wherein

R^1, R^2 and R^3 ~~is~~ are hydrogen~~; a branched or straight C_1-C_6 alkyl; C_1-C_6 alkenyl; C_3-C_8 cycloalkyl; C_4-C_8(alkyl-cycloalkyl), wherein alkyl is C_1-C_2 alkyl and cycloalkyl is C_3-C_6 cycloalkyl; C_6-C_{10} aryl or heteroaryl having from 5 to 10 atoms selected from C, S, N and/or O, wherein said aryl and/or heteroaryl may optionally and independently be substituted by 1 or 2 substituents selected from hydrogen, CH_3, $(CH_2)_pCF_3$, halogen, $CONR^5R^4$, $COOR^5$, COR^5, $(CH_2)_pNR^5R^4$, $(CH_2)_pCH_3$, $(CH_2)_pSOR^5$, $(CH_2)_pSO_2R^5$, $(CH_2)_pSO_2NR^5R^4$ and $(CH_2)_pOR^5$, wherein p is 0, 1 or 2; (C_1-C_2 alkyl)-(C_6-C_{10} aryl) or (C_1-C_2 alkyl)heteroaryl, wherein said heteroaryl has from 5 to 10 atoms selected from C, S, N and/or O, and wherein said aryl and/or heteroaryl may optionally and independently be substituted by 1 or 2 substituents selected from hydrogen, CH_3, $-(CH_2)_qCF_3$, halogen, $-CONR^5R^4$, $-COOR^5$, $-COR^5$, $-(CH_2)_qNR^5R^4$, $-(CH_2)_qCH_3$, $(CH_2)_qSOR^5$, $-(CH_2)_qSO_2R^5$, $-(CH_2)_qSO_2NR^5R^4$, and $-(CH_2)_qOR^5$, wherein q is 0, 1 or 2; and~~



,



, or



~~, wherein R^{18}, R^{19}, R^{20}, R^{21}, R^{22}, R^{23}, and R^{24} is each and independently selected from hydrogen, C_1-C_6 alkyl, and C_1-C_6 alkenyl;~~

~~R^2 and R^3 is each and independently selected from hydrogen and C_1-C_6 alkyl;~~

A is



, wherein the phenyl ring of is optionally and independently substituted by 1 or 2 substituents Z^1 and Z^2 each and independently selected from hydrogen, CH_3, $-(CH_2)_rCF_3$, halogen, $-CONR^6R^7$, $-CO_2R^6$, $-COR^6$, $-(CH_2)_rNR^6R^7$, $-(CH_2)_rCH_3$, $-(CH_2)_rSOR^6$, $-(CH_2)_rSO_2R^6$ and $-(CH_2)_rSO_2NR^6R^7$, wherein r is 0, 1, or 2;

Q is C_5-C_6 hydroaryl; heterohydroaromatic having 5 or 6 atoms selected from C, S, N and/or O; C_5-C_6 cycloalkyl; or C_5-C_6 heterocycloalkyl having 5 or 6 atoms selected from C, N, and O and/or S; and wherein each Q is optionally substituted by a subsitutent Z^1 and Z^2 as defined above; and

B is phenyl or naphthyl, wherein the phenyl and naphthyl is optionally and independently substituted by 1 or 2 substituents selected from hydrogen and , CH_3, $-(CH_2)_tCF_3$, halogen, $-(CH_2)_tCONR^5R^4$, $-(CH_2)_tNR^5R^4$, $-(CH_2)_tCOR^5$, $-(CH_2)_tCOOR^5$, $-OR^5$, $-(CH_2)_tSOR^5$, $-(CH_2)_tSO_2R^5$, and $-(CH_2)_tSO_2NR^5R^4$, wherein t is 0, 1, 2 or 3; and

R^4, R^5, R^6, and R^7 is each and independently selected from hydrogen; a branched or straight C_1-C_6 alkyl; C_1-C_6 alkenyl; C_3-C_8 cycloalkyl; and C_4-C_8(alkyl-cycloalkyl), wherein alkyl is C_1-C_2 alkyl and cycloalkyl is C_3-C_6 cycloalkyl;

as well as pharmaceutically acceptable salts of the compounds of the formula (I), and isomers, hydrates, and isoforms and prodrugs thereof.

2. (currently amended) A compound of the formula (I) according to claim 1, wherein


A is , wherein the phenyl ring of A is optionally and independently substituted at any position of the phenyl ring by 1 or 2 substituents Z^1 and Z^2 which is each and independently selected from hydrogen, CH_3, $-(CH_2)_rCF_3$, halogen, $-CONR^6R^7$, $-COOR^6$, $-COR^6$, -

~~$(CH_2)_rNR^6R^7$, $-(CH_2)_rCH_3$, $-(CH_2)_rSOR^6$, $-(CH_2)_rSO_2R^6$ and $-(CH_2)_rSO_2NR^6R^7$, wherein r is 0, 1, or 2;~~

Q is morpholine, piperidine, or pyrrolidine;

as well as pharmaceutically acceptable salts of the compounds of the formula (I), and isomers, hydrates, and isoforms thereof.

~~R^1 is hydrogen; a branched or straight C_1-C_4 alkyl; C_3-C_5 cycloalkyl; C_4-C_8 (alkyl-cycloalkyl), wherein alkyl is C_1-C_2 alkyl and cycloalkyl is C_3-C_6 cycloalkyl; and C_6-C_{10} aryl or heteroaryl having from 5 to 6 atoms selected from C, S, N and/or O, wherein the aryl and/or heteroaryl is optionally and independently substituted by 1 or 2 substituents selected from hydrogen, CH_3, $-(CH_2)_pCF_3$, halogen, $-CONR^5R^4$, $-COOR^5$, $-COR^5$, $-(CH_2)_pNR^5R^4$, $-(CH_2)_pCH_3$, $-(CH_2)_pSOR^5$, $-(CH_2)_pSO_2R^5$, and $-(CH_2)_pSO_2NR^5R^4$, wherein p is 0, 1 or 2;~~

~~B is phenyl or naphthyl, wherein the phenyl and naphthyl is optionally and independently substituted by 1 or 2 substituents selected from hydrogen, CH_3, CF_3, halogen, $-(CH_2)_qCONR^5R^4$, $-(CH_2)_qNR^5R^4$, $-(CH_2)_qCOR^5$, $-(CH_2)_qCO_2R^5$, and $-OR^5$; wherein q is 0 or 1;~~

~~R^4, R^5, R^6, and R^7, is each and independently selected from hydrogen, a branched or straight C_1-C_6 alkyl, C_1-C_6 alkenyl, C_3-C_8 cycloalkyl, and C_4-C_8(alkyl-cycloalkyl) wherein alkyl is C_1-C_2 alkyl and cycloalkyl is C_3-C_6 cycloalkyl; and~~

~~R^2 and R^3 is each and independently selected from hydrogen and methyl~~.

3. (canceled)

4. (currently amended) A compound ~~of the formula (I) according to claim 1,~~ which ~~compound~~ is



, wherein R is morpholine, piperidine or pyrrolidine;

as well as pharmaceutically acceptable salts of the compounds of the formula (I), and isomers, hydrates, and isoforms thereof.

.

5. (canceled).

6. (previously presented) A compound according to claim 1, in form of its hydrochloride, sulfate, tartrate or citrate salts.

7-14. (canceled)

15. (previously presented) A compound according to claim 1, wherein said compound is isotopically labelled.

16. (canceled).

17. (original) An isotopically labelled compound of the formula (I) of claim 1.

18. (canceled).

19. (original) A pharmaceutical composition comprising a compound of the formula (I) according to claim 1 as an active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier.

20-26. (canceled)

27. (previously presented) A compound according to claim 4, in form of its hydrochloride, sulfate, tartrate or citrate salts.

28. (previously presented) A pharmaceutical composition comprising a compound of the formula (I) according to claim 4 as an active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier.

29. (previously presented) A compound according to claim 2, wherein B is a phenyl substituted by 1 substituent selected from halogen.

30. (previously presented) A compound according to claim 29, wherein the halogen is fluorine.

31. (previously presented) A compound according to claim 30, wherein said phenyl is substituted at the meta position by said fluorine.

~~31.~~ 32. (currently amended) A compound according to claim 4 ~~29~~, wherein R is morpholin-4-yl, piperidinyl, or pyrrolidinyl ~~Z^1, Z^2, and R^1 is each and independently H; and R^2 and R^3 is each and independently selected from H and CH_3~~.

~~32~~ 33. (currently amended) A compound according to claim 2 ~~31~~, wherein Q is morpholin-4-yl, piperidinyl, or pyrrolidinyl ~~Z^1, Z^2, R^1, R^2, and R^3 is each and independently H~~.

~~33~~ 34. (currently amended) A compound according to claim 4, wherein said compound is isotopically labeled ~~29, wherein Z^1, Z^2, R^1, R^2, and R^3 is each and independently H~~.

~~34~~35. (currently amended) A compound according to claim 4, wherein ~~said compound is isotopically labeled~~ the compound is selected from:

4-[(3-fluorophenyl)-piperidin-4-yl-methyl]-phenyl-morpholin-4-yl-methanone;

4-[(3-fluorophenyl)-piperidin-4-yl-methyl]-phenyl-piperidin-1-yl-methanone; and

4-[(3-fluorophenyl)-piperidin-4-yl-methyl]-phenyl-pyrolidin-1-yl-methanone.

~~35~~36. (currently amended). A compound according to claim 1 ~~claim 4~~, wherein Q is a C_5-C_6 heterocycloalkyl having 5 or 6 atoms selected from C, N, and O ~~the compound is selected from:~~

~~4-[(3-fluorophenyl)-piperidin-4-yl-methyl]-phenyl-morpholin-4-yl-methanone;~~

~~4-[(3-fluorophenyl)-piperidin-4-yl-methyl]-phenyl-piperidin-1-yl-methanone; and~~

~~4-[(3-fluorophenyl)-piperidin-4-yl-methyl]-phenyl-pyrolidin-1-yl-methanone~~.